Navigation Links
Inflamax Research Appoints ,Dr. Anne Marie Salapatek President & Chief Scientific Officer
Date:2/18/2013

Toronto, Ontario (PRWEB) February 18, 2013

Dr. Salapatek is an internationally renowned scientist with expertise in allergy, asthma and EEC clinical trials. Previously she was the Principal Scientist at Cetero Research (formerly Allied Research International) where she was responsible for the development and validation of new Allergy and Asthma clinical models, advising clients on study designs including utilizing EEC technology for seasonal and perennial allergies, asthma, non-allergic rhinoconjunctivitis and COPD. Dr. Salapatek has worked with many clients to realize their drug development program goals by providing expert study design, regulatory strategy, and data analysis and interpretation. Dr Salapatek has presented her research at numerous international meetings including the FDA workshops and Advisory Panels on the utility of Environmental Exposure Chambers in pivotal, Phase 3 studies.

“I have worked with Anne Marie before and I am delighted that she has joined us at Inflamax Research, where her extensive experience in Environmental Exposure Chambers and drug development will prove invaluable to our clients,“ said Dr. Piyush Patel, Inflamax’s CEO. “Dr. Salapatek has close working relationships with numerous key opinion leaders and scientists in the pharmaceutical industry, as well, she has a proven track record in designing and overseeing complex Phase 1 to 4 clinical trials She brings a high caliber of scientific credibility, rigor and integrity which is at the core of Inflamax’s approach to clinical research. With the addition of Dr. Salapatek’s expertise to our science team, Inflamax now has unparalleled capability to design and perform complex large and small clinical trials using EEC technology."

“I am excited to join Inflamax Research and look forward to helping to lead and shape a company that has as its core tenet: “Scientific Excellence in Clinical Research”.” said Dr. Salapatek. “ I am pleased to work with the high caliber staff at Inflamax who are extremely skilled and experienced in the field of EEC and allergy/asthma research. I look forward to working with our clients who are engaged in the development of future medications and who deserve the best service in these critically important endeavors.”

Dr. Anne Marie Salapatek has over 20 years’ research experience both in industry and academia. She is the author of over 100 publications including patent inventions in topics ranging from inflammatory mechanisms to clinical trial design, conduct and Environmental Exposure Chamber technology. Dr. Salapatek was awarded a Ph.D. in Pharmacology from McMaster University, MSc in Physiology and BSc in Biochemistry from University of Toronto, Canada. Dr. Salapatek was the recipient of Canadian Institute of Health Research’s Principal Investigator funding and appointed Assistant Professor in the Faculty of Medicine at the University of Toronto conducting well-funded research in the areas of respiratory, diabetes and gastroenterology. She was the recipient from the Lieutenant Governor of Ontario of the prestigious John Polanyi Prize (Nobel laureate) recognizing excellence in research in Canada. Dr. Salapatek brings to Inflamax Research a strong academic background coupled with extensive experience in clinical drug development in partnership with client Sponsors. She has advocated the use of the EEC model for allergy and dry eye research in regulatory and research forums demonstrating their benefit to improving the accuracy and precision of clinical research.

About Inflamax

Inflamax is a full service Contract Research Organization (CRO) specializing in Proof of Concept as well as Phase I through IV studies in allergy, asthma, ocular disease and dermatology, utilizing EEC technology. Inflamax conducts single and multi-center Environmental Exposure Chamber (EEC) and field studies. In addition to Inflamax Research’s Mobile EEC™ systems which can be positioned globally, Inflamax has 2 fixed EECs at Inflamax headquarters in Toronto, Canada. Inflamax’s EECs have been validated for study of allergy to ragweed and grass and also for the study of dry eye syndrome (utilizing low humidity EEC conditions). Validations are currently in process for cat and dust mite allergens and are expected to be completed in Q1’2013, thereby making the EECs suitable for clinical studies to test medications for perennial allergies.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10429097.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
2. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection
3. Wolters Kluwer Research Now Available via Bloomberg Tradebook
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
6. Researching graphene nanoelectronics for a post-silicon world
7. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
8. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. Multidisciplinary team of researchers develop world’s lightest material
11. K computer research results awarded ACM Gordon Bell Prize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight Against ... Cancer Research (OICR) are pleased to report that Fusion ... financing, with Johnson & Johnson Innovation – JJDC, Inc. ... venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, ... ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... ... Today, researchers can fast-track sample collection and analysis for ... or SNPs of interest) using one, easy-to-collect saliva sample. With the addition of ... and other relevant biomarkers can be extensively studied through a non-invasive sample type. ...
Breaking Biology Technology:
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):